TSLA
Tesla
-- 222.150 NVDA
NVIDIA
-- 106.980 PLTR
Palantir
-- 76.380 AAPL
Apple
-- 227.480 MSTR
Strategy
-- 239.270 
NEWS
iBio Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBio
Tuesday, 7th January at 7:00 am
SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- iBio, Inc.(NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, in collaboration with AstralBio Inc., announced today the development of an antibody that inhibits the function of Activin E, a promising therapeutic target for cardiometabolic disorders and obesity using iBio's patented Machine-Learning Antibody Engine. Developing an antibody against Activin E, a challenging and elusive target, highlights the robust capabilities of the technology to deliver innovative therapeutics, and contributes to iBio's pipeline of development candidates. iBio plans to rapidly advance testing of this molecule and additional candidates in more complex and disease relevant models.
"Developing a functional antibody against Activin E, an achievement we believe to be an industry first, is a significant milestone for iBio," said Martin Brenner, Ph.D., DVM, iBio's Chief Executive Officer and Chief Scientific Officer. "This breakthrough strengthens our efforts to expand our therapeutics pipeline for the treatment of cardiometabolic disorders and obesity with innovative next-generation solutions. We are excited about this program's advancement and our recently announced programs targeting Myostatin and Activin A as we build a pipeline of development candidates to address areas of high unmet need. This accomplishment also underscores the power and potential of our Machine Learning Antibody Engine in overcoming hard-to-drug targets and addressing some of the most pressing challenges in antibody discovery and development."
Human genetics provide strong evidence for Activin E as a thera
Tuesday, 7th January at 7:00 am
SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- iBio, Inc.(NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, in collaboration with AstralBio Inc., announced today the development of an antibody that inhibits the function of Activin E, a promising therapeutic target for cardiometabolic disorders and obesity using iBio's patented Machine-Learning Antibody Engine. Developing an antibody against Activin E, a challenging and elusive target, highlights the robust capabilities of the technology to deliver innovative therapeutics, and contributes to iBio's pipeline of development candidates. iBio plans to rapidly advance testing of this molecule and additional candidates in more complex and disease relevant models.
"Developing a functional antibody against Activin E, an achievement we believe to be an industry first, is a significant milestone for iBio," said Martin Brenner, Ph.D., DVM, iBio's Chief Executive Officer and Chief Scientific Officer. "This breakthrough strengthens our efforts to expand our therapeutics pipeline for the treatment of cardiometabolic disorders and obesity with innovative next-generation solutions. We are excited about this program's advancement and our recently announced programs targeting Myostatin and Activin A as we build a pipeline of development candidates to address areas of high unmet need. This accomplishment also underscores the power and potential of our Machine Learning Antibody Engine in overcoming hard-to-drug targets and addressing some of the most pressing challenges in antibody discovery and development."
Human genetics provide strong evidence for Activin E as a thera
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment